Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Capecitabine EP Impurity G
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 95 %
Hazard Compound
No -Refer MSDS for accurate information
2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentoxycarbonxyl)cytidine is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentoxycarbonxyl)cytidine usage and description
2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentoxycarbonxyl)cytidine, also known as DFP-10917, is a novel nucleoside analogue that has demonstrated potent antitumor activity in preclinical studies. This compound is a prodrug of 5-fluorouracil, which is a widely used chemotherapeutic agent for the treatment of various types of cancer. DFP-10917 is designed to selectively target cancer cells while minimizing toxicity to normal cells.
The chemical structure of DFP-10917 consists of a cytidine base modified with a pentoxycarbonyl group at the N4 position and a 5-fluoro substituent at the 5' position. The cytidine base is an essential component of DNA and RNA, and its modification with the pentoxycarbonyl and 5-fluoro groups enhances the compound's antitumor activity by interfering with DNA synthesis and repair.
DFP-10917 is primarily administered intravenously and undergoes rapid conversion to 5-fluorouracil in the body. The prodrug form of DFP-10917 allows for targeted delivery of the active drug to cancer cells, which may enhance its efficacy and reduce side effects. Preclinical studies have shown that DFP-10917 is effective against a range of cancer types, including breast, lung, and colon cancers.
In summary, DFP-10917 is a promising antitumor agent that has shown potent activity against various types of cancer in preclinical studies. Its unique chemical structure and prodrug formulation may offer advantages over existing chemotherapy drugs by providing targeted delivery and minimizing toxicity to normal cells. Further clinical development of DFP-10917 is warranted to determine its safety and efficacy in human patients.
